What did tesamorelin trials measure? Two placebo-controlled phase III trials assessed visceral adipose tissue at week 26 in adults with HIV-associated abdominal lipohypertrophy. Mean VAT change was -18% versus +2% in one study and -14% versus -2% in the other. These are within-group changes from baseline, not a 15% to 18% difference versus placebo. The trials did not establish a week-by-week before-and-after timeline or a general weight-loss result.
Sources: FDA-approved prescribing information, clinical studies tables; phase III trial report, PMID 20101189.
Trust Signals
Key Takeaways
- At week 26, mean VAT change was -18% versus +2% in one phase III study and -14% versus -2% in the second. The trials enrolled adults with HIV-associated abdominal lipohypertrophy.
- The registration trials assessed the primary VAT endpoint at week 26; they do not establish a week-by-week response timeline.
- In the 26-week extension, participants switched from tesamorelin to placebo had mean VAT increases of 22% and 16% from week 26 to week 52; participants who continued tesamorelin had changes of 0% and -5%. These group results do not establish that every person returns to baseline on a fixed 24-week schedule.
- The FDA-approved indication is narrow: HIV-associated lipohypertrophy only. All wellness and anti-aging use is off-label with no equivalent RCT backing.
- Glucose impairment is a documented risk: fasting glucose and HbA1c increased significantly in trial participants, requiring active monitoring.
What Are Tesamorelin Peptide Before and After Results, in Plain Terms?
In two placebo-controlled phase III trials in adults with HIV-associated abdominal lipohypertrophy, mean VAT changed -18% versus +2% in one study and -14% versus -2% in the other at week 26. These are changes from baseline within each group. The studies did not establish a general weight-loss effect or results for adults without that trial population.
From the FormBlends catalog
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →Table of Contents
- What is tesamorelin and why does it affect fat?
- How long does it take to see results from tesamorelin?
- Evidence ledger: grading every major claim
- Mechanism with specific numbers
- What most pages get wrong about tesamorelin results
- Honest head-to-head: tesamorelin vs. alternatives
- What tesamorelin before and after pictures actually show
- Chemistry behind storage and stability rules
- Operational guide: label literacy, dosing, COA reading
- Side effects and monitoring
- FAQ
- Sources
What Is Tesamorelin and Why Does It Affect Fat?
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), a 44-amino-acid peptide. It binds the GHRH receptor on pituitary somatotroph cells, triggering pulsatile release of endogenous growth hormone. That GH rise stimulates hepatic IGF-1 production. IGF-1 and GH together promote lipolysis in visceral adipocytes, which express relatively more GH receptors than subcutaneous fat depots. This receptor-density difference is the mechanistic reason tesamorelin preferentially reduces visceral fat rather than subcutaneous fat.
Critically, tesamorelin does not deliver exogenous GH. It works upstream, preserving the pituitary feedback axis, which is partly why the FDA approved it over direct GH formulations for this indication.
How Long Does It Take to See Results from Tesamorelin?
The registration trials report a primary VAT endpoint at week 26. The published results do not establish measured response milestones at weeks 4, 8 to 12, or 12 to 16.
| Timepoint | What to Expect | Evidence Basis |
|---|---|---|
| Week 26 primary endpoint | Study 1: VAT changed -18% with tesamorelin and +2% with placebo. Study 2: -14% with tesamorelin and -2% with placebo. | Two phase III registration trials in adults with HIV-associated abdominal lipohypertrophy |
| Weeks 26 to 52 extension | After switching to placebo: +22% and +16%. With continued tesamorelin: 0% and -5%. | Extension groups from the same trials; changes measured from week 26 |
The published registration studies report their primary visceral-fat result at week 26. They do not establish a clinical before-and-after schedule at one, two, or three months.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Visceral fat reduction at 26 weeks (HIV-lipohypertrophy) | Human RCT, phase III (Falutz et al.) | Mean within-group VAT change of -14% to -18% at week 26 | High |
| IGF-1 increase with 2 mg daily dosing | Human RCT, phase III | Positive, substantial increase from baseline reported across both trial arms | High |
| VAT rebound after discontinuation | Human RCT follow-up data | Negative (reversal of benefit) | Moderate |
| Cognitive improvement in older adults | Single human RCT (Baker et al., 2012) | Positive on executive function tests | Low to Moderate |
| Visceral fat reduction in healthy adults without HIV | No equivalent RCT; extrapolation from mechanism | Plausible but unquantified | Very Low |
| Subcutaneous fat reduction | Phase III trials: non-significant | Neutral | High (for lack of effect) |
| Muscle mass increase | Secondary endpoints; modest lean mass signal | Small positive trend, not primary endpoint | Low |
| Anti-aging or longevity benefit | Mechanism only | Speculative | Very Low |
Mechanism with Specific Numbers
Tesamorelin's 44-amino-acid sequence mirrors endogenous GHRH(1-44) with the addition of a trans-3-hexenoic acid moiety at the N-terminus. That modification extends plasma half-life from the roughly 7-minute half-life of native GHRH to approximately 26 minutes for tesamorelin, per Theratechnologies pharmacokinetic data supporting the NDA. The longer half-life allows once-daily subcutaneous dosing to generate measurable GH pulses.
In the Falutz et al. trials reported in JAIDS (2010) and the earlier NEJM publication (2007), tesamorelin 2 mg daily produced, across the two multicenter phase III studies:
- Mean VAT reduction in the range of approximately 37 to 45 cm squared on CT cross-section versus placebo-associated increases (figures drawn from the pooled JAIDS 2010 analysis)
- Substantial IGF-1 increases from baseline in the tesamorelin group versus placebo, with the magnitude differing between the two trials; exact mcg/L figures are reported in the primary publications and the FDA label
- No statistically significant change in subcutaneous adipose tissue
- Waist circumference reduction of approximately 2.5 cm versus placebo at 26 weeks
What this mechanism does NOT prove: A GH pulse triggered by tesamorelin in someone with normal GH secretion may produce a blunted incremental effect compared to the GH-dysregulated state typical in HIV-associated lipohypertrophy. The magnitude of fat loss in healthy adults with normal GH axes is genuinely unknown and almost certainly smaller than trial-reported figures.
What Most Pages Get Wrong About Tesamorelin Results
Additional omissions on most competitor pages:
- In the 26-week extension, groups that switched from tesamorelin to placebo had mean VAT increases from week 26 to week 52. The extension results describe group averages, not a guaranteed individual response. No maintenance protocol eliminates VAT rebound after stopping. The biology of stimulatory peptides means effect exists only while the stimulus continues.
- Subcutaneous fat does not respond. Most users hoping for overall fat loss are targeting subcutaneous depots. Tesamorelin's phase III data show no significant subcutaneous fat change. Users who do not carry large visceral fat burdens may see almost no visible change.
- Glucose risk is real and frequently omitted. The FDA label carries a warning about glucose impairment. This is not a theoretical concern; it was a trial-measured finding requiring active monitoring.
- Purity of compounded or research-grade tesamorelin varies widely. The FDA-approved Egrifta SV product has validated pharmaceutical-grade purity. Peptides sourced from research chemical suppliers may have substantially different purity, unknown impurities, and inconsistent amino-acid sequences.
Honest Head-to-Head: Tesamorelin vs. Alternatives
| Compound | Evidence for Fat Loss | VAT Specificity | Reversibility | Regulatory Status | Where It Loses |
|---|---|---|---|---|---|
| Tesamorelin | Phase III RCT in HIV-lipohypertrophy | High (visceral selective) | Full rebound on stopping | FDA approved (narrow indication) | No data in healthy adults; daily injection; glucose risk |
| CJC-1295 | No phase III fat-loss RCT | Unknown | Similar (stimulatory mechanism) | Not FDA approved; research compound | Evidence gap is enormous vs. tesamorelin |
| Semaglutide (GLP-1 RA) | Multiple large RCTs; 10 to 17% total body weight loss | Both visceral and subcutaneous | Partial rebound on stopping | FDA approved (obesity, T2D) | Tesamorelin has no nausea/GI burden; different mechanism |
| Sermorelin | Phase II only; small samples | Not established | Similar | Compounded; original approval withdrawn | Weaker evidence; shorter half-life requires more frequent dosing |
| Ipamorelin | Animal and small human studies only | Not established | Similar | Research compound | No human RCT body composition data |
Tesamorelin wins on evidence quality for visceral fat in its approved population. It loses on generalizability, route of administration, glucose safety profile, and cost compared to most research peptides.
What Tesamorelin Before and After Pictures Actually Show
Published clinical photos and CT reconstructions from the Egrifta registration program show reduction in lower-abdominal convexity in HIV-positive participants after 26 weeks at 2 mg daily. The visible changes are real and documented in peer-reviewed literature, not anecdote.
In general wellness users without lipohypertrophy:
- No equivalent peer-reviewed photographic dataset exists.
- Anecdotal before-and-after images circulating on forums and practitioner sites are not controlled, not blinded, and confounded by concurrent caloric restriction, exercise, and other compounds.
- A healthy adult with a small visceral fat compartment has less absolute VAT to lose, so the same percentage reduction produces a less visible change than in the trial population.
Treat social media before-and-after images as marketing, not evidence. The only reliable before-and-after data come from the Falutz et al. trials and the Egrifta clinical development program.
Chemistry Behind Storage and Stability Rules
Tesamorelin is a polypeptide. Its degradation follows two primary pathways:
- Peptide bond hydrolysis: Water molecules attack amide bonds along the 44-amino-acid chain. This reaction is temperature-dependent and follows Arrhenius kinetics: every 10 degrees Celsius increase roughly doubles the hydrolysis rate. Storing tesamorelin at room temperature (approximately 22 to 25 degrees Celsius) instead of 2 to 8 degrees Celsius therefore substantially accelerates degradation, though specific published rate constants for tesamorelin under room-temperature storage are not publicly available in granular form.
- Oxidation: Methionine residues and the trans-3-hexenoic acid modification are susceptible to oxidative degradation, particularly in the presence of light and dissolved oxygen. This is why tesamorelin should be protected from light and why some formulations use nitrogen headspace in vials.
Reconstituted peptide in bacteriostatic water degrades faster than lyophilized powder because water is required for hydrolysis and because the stabilizing effects of the crystalline lyophilized state are lost. The Egrifta SV label specifies use within 24 hours of reconstitution when refrigerated. Research-grade vials often carry the same recommendation, but without pharmaceutical-grade excipient formulation, the actual stability window may be shorter. A degraded peptide solution may appear visually identical to an intact one; color, clarity, and particulates are unreliable potency indicators for peptide degradation.
Operational Guide: Label Literacy, Dosing, and COA Reading
Dosing
| Context | Dose | Frequency | Evidence Basis |
|---|---|---|---|
| FDA-approved (HIV-lipohypertrophy) | 2 mg | Once daily, subcutaneous | Phase III RCT |
| Off-label wellness (reported) | 1 to 2 mg | Once daily, subcutaneous | No controlled trial; clinician extrapolation |
Reconstitution Math
A common research vial contains 2 mg of lyophilized tesamorelin. Adding 1 mL of bacteriostatic water yields a 2 mg/mL solution. A 0.1 mL draw (10 units on a U-100 insulin syringe) delivers 0.2 mg. For the 2 mg clinical dose, a full 1 mL draw is required. Confirm your vial concentration before drawing; errors in this calculation directly affect dose accuracy.
Reading a Certificate of Analysis (COA)
For any non-pharmaceutical tesamorelin source, request a COA that includes:
- Purity by HPLC: look for above 98% as a minimum threshold for research-grade material
- Mass confirmation by mass spectrometry (LC-MS) confirming molecular weight matches the expected 5135 Da for tesamorelin
- Endotoxin testing (LAL test): bacterial endotoxins cause injection-site inflammation and systemic fever; a COA without endotoxin data is incomplete
- Water content by Karl Fischer titration: high water content reduces actual peptide mass per vial
A COA issued by the same company selling the peptide is not independent verification. Third-party testing from an ISO-accredited lab carries more weight.
Side Effects and Monitoring
From phase III trial data (Falutz et al.):
| Adverse Effect | Frequency in Trials | Clinical Relevance |
|---|---|---|
| Injection site reactions (erythema, pruritus) | Most common; majority were mild | Low clinical severity; rotate injection sites |
| Peripheral edema and fluid retention | Reported in treatment group vs. placebo | GH-related sodium retention; usually transient |
| Arthralgia and myalgia | Reported, more frequent than placebo | GH-related; dose-limiting in some participants |
| Glucose impairment (fasting glucose, HbA1c increase) | Statistically significant vs. placebo | Clinically important; screen for pre-diabetes; monitor quarterly |
| IGF-1 elevation | Expected pharmacodynamic effect | Monitor to confirm activity; very high IGF-1 may warrant dose adjustment |
Tesamorelin is contraindicated in malignancy (GH can stimulate tumor growth via IGF-1), in pregnancy, and in individuals with disrupted hypothalamic-pituitary axis from non-HIV causes. These are hard contraindications, not theoretical cautions.
FAQ
What did the phase III tesamorelin trials measure?
They measured visceral adipose tissue at week 26 in adults with HIV-associated abdominal lipohypertrophy. Study 1 reported mean changes of -18% with tesamorelin and +2% with placebo; Study 2 reported -14% and -2%. These are changes from baseline within each group.
Did the trials establish a week-by-week results timeline?
No. The published registration studies report their primary visceral-fat endpoint at week 26 and do not establish measured response milestones at weeks 12 to 16.
What happened in the trial extension after some participants switched to placebo?
From week 26 to week 52, mean visceral-fat changes were +22% and +16% in the groups that switched to placebo, and 0% and -5% in the groups that continued tesamorelin. The extension reports group changes over that interval, not a fixed time for each participant to return to baseline.
Do these trial percentages describe results in all adults?
No. The registration trials studied adults with HIV-associated abdominal lipohypertrophy. Their averages do not establish the effect in populations that were not studied.
Sources
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. JAIDS. 2010;53(3):311-322.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.
- FDA. Egrifta SV (tesamorelin for injection) Prescribing Information. Theratechnologies Inc. Available at: FDA.gov.
- Theratechnologies Inc. Tesamorelin pharmacokinetic data submitted as part of NDA 022505. FDA Drug Approval Package. 2010.
- Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65.
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(1):17-18.
Footer Disclaimers
Platform: FormBlends is an information and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before initiating any peptide protocol.
Research Compound Notice: Tesamorelin outside of the FDA-approved Egrifta SV product is classified as a research compound in most jurisdictions. Its purchase, possession, and use outside a licensed clinical setting may be subject to regulatory restrictions. Verify the legal status in your jurisdiction before sourcing.
Results Disclaimer: Individual results vary. The effect sizes reported on this page come from a specific clinical population (HIV-positive adults with lipohypertrophy) and may not reflect outcomes in healthy adults or other populations.
Trademark: Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. FormBlends has no affiliation with Theratechnologies Inc. All third-party trademarks are the property of their respective owners.
Related peptide guides
Ready when you are
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →